Commentary on "Principal Stratification -- a Goal or a Tool?" by Judea Pearl : The International Journal of Biostatistics uses cookies, tags, and tracking settings to store information that help give you the very best browsing experience.
To understand more about cookies, tags, and tracking, see our Privacy Statement
I accept all cookies for the De Gruyter Online site

Jump to ContentJump to Main Navigation

The International Journal of Biostatistics

Ed. by Chambaz, Antoine / Hubbard, Alan E. / van der Laan, Mark J.

IMPACT FACTOR 2014: 0.741
5-year IMPACT FACTOR: 1.475

SCImago Journal Rank (SJR) 2014: 1.247
Source Normalized Impact per Paper (SNIP) 2014: 1.078
Impact per Publication (IPP) 2014: 1.206

Mathematical Citation Quotient (MCQ) 2014: 0.07

Commentary on "Principal Stratification -- a Goal or a Tool?" by Judea Pearl

Peter B. Gilbert1 / Michael G. Hudgens2 / Julian Wolfson3

1Fred Hutchinson Cancer Research Center & University of Washington

2University of North Carolina at Chapel Hill

3University of Minnesota, Twin Cities

Citation Information: The International Journal of Biostatistics. Volume 7, Issue 1, Pages 1–15, ISSN (Online) 1557-4679, DOI: 10.2202/1557-4679.1341, September 2011

Publication History

Published Online:

This commentary takes up Pearl's welcome challenge to clearly articulate the scientific value of principal stratification estimands that we and colleagues have investigated, in the area of randomized placebo-controlled preventive vaccine efficacy trials, especially trials of HIV vaccines. After briefly arguing that certain principal stratification estimands for studying vaccine effects on post-infection outcomes are of genuine scientific interest, the bulk of our commentary argues that the “causal effect predictiveness” (CEP) principal stratification estimand for evaluating immune biomarkers as surrogate endpoints is not of ultimate scientific interest, because it evaluates surrogacy restricted to the setting of a particular vaccine efficacy trial, but is nevertheless useful for guiding the selection of primary immune biomarker endpoints in Phase I/II vaccine trials and for facilitating assessment of transportability/bridging surrogacy.

Keywords: principal stratification; causal inference; vaccine trial

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Hannah Ensor, Robert J. Lee, Cathie Sudlow, and Christopher J. Weir
Journal of Biopharmaceutical Statistics, 2015, Page 150921221440007
Peter B. Gilbert, Erin E. Gabriel, Xiaopeng Miao, Xiaoming Li, Shu-Chih Su, Janie Parrino, and Ivan S. F. Chan
Journal of Infectious Diseases, 2014, Volume 210, Number 10, Page 1573
Barton F. Haynes, Peter B. Gilbert, M. Juliana McElrath, Susan Zolla-Pazner, Georgia D. Tomaras, S. Munir Alam, David T. Evans, David C. Montefiori, Chitraporn Karnasuta, Ruengpueng Sutthent, Hua-Xin Liao, Anthony L. DeVico, George K. Lewis, Constance Williams, Abraham Pinter, Youyi Fong, Holly Janes, Allan DeCamp, Yunda Huang, Mangala Rao, Erik Billings, Nicos Karasavvas, Merlin L. Robb, Viseth Ngauy, Mark S. de Souza, Robert Paris, Guido Ferrari, Robert T. Bailer, Kelly A. Soderberg, Charla Andrews, Phillip W. Berman, Nicole Frahm, Stephen C. De Rosa, Michael D. Alpert, Nicole L. Yates, Xiaoying Shen, Richard A. Koup, Punnee Pitisuttithum, Jaranit Kaewkungwal, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Nelson L. Michael, and Jerome H. Kim
New England Journal of Medicine, 2012, Volume 366, Number 14, Page 1275
Ying Huang, Peter B. Gilbert, and Julian Wolfson
Biometrics, 2013, Volume 69, Number 2, Page 301

Comments (0)

Please log in or register to comment.